Baker Avenue Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Baker Avenue Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-264	Closed	-$32.3K	–	877
2023 Q3	$32.3K	Hold	264	–	–	﹤0.01%	579
2023 Q2	$33.5K	Sell	264 -2,120	-89%	-$275K	﹤0.01%	577
2023 Q1	$308K	Buy	2,384 +1,070	+81%	+$140K	0.02%	303
2022 Q4	$173K	Sell	1,314 -2,381	-64%	-$308K	0.01%	337
2022 Q3	$432K	Buy	3,695 +1,737	+89%	+$216K	0.03%	249
2022 Q2	$230K	Sell	1,958 -53,373	-96%	-$6.34M	0.02%	288
2022 Q1	$7.21M	Buy	55,331 +2,898	+6%	+$377K	0.37%	74
2021 Q4	$8M	Buy	52,433 +4,469	+9%	+$692K	0.4%	69
2021 Q3	$7.75M	Buy	47,964 +1,122	+2%	+$189K	0.44%	60
2021 Q2	$7.67M	Buy	46,842 +6,955	+17%	+$1.07M	0.44%	59
2021 Q1	$6M	Buy	39,887 +324	+0.8%	+$51.5K	0.37%	67
2020 Q4	$5.99M	Sell	39,563 -627	-2%	-$89.6K	0.41%	62
2020 Q3	$5.44M	Sell	40,190 -1,966	-5%	-$267K	0.42%	54
2020 Q2	$5.76M	Sell	42,156 -7,263	-15%	-$926K	0.47%	47
2020 Q1	$5.32M	Sell	49,419 -59,879	-55%	-$6.89M	0.63%	28
2019 Q4	$13.2M	Buy	109,298 +4,672	+4%	+$521K	0.95%	23
2019 Q3	$10.4M	Buy	104,626 +589	+0.6%	+$61.7K	0.83%	29
2019 Q2	$11.3M	Sell	104,037 -1,924	-2%	-$205K	0.92%	27
2019 Q1	$11.8M	Sell	105,961 -8,806	-8%	-$966K	0.98%	25
2018 Q4	$11.1M	Buy	114,767 +71,837	+167%	+$7.62M	1.09%	25
2018 Q3	$5.24M	Sell	42,930 -58	-0.1%	-$6.83K	0.43%	65
2018 Q2	$4.72M	Sell	42,988 -104	-0.2%	-$11.1K	0.41%	63
2018 Q1	$4.6M	Buy	43,092 +938	+2%	+$104K	0.42%	64
2017 Q4	$4.5M	Buy	42,154 +469	+1%	+$50.1K	0.43%	61
2017 Q3	$4.63M	Sell	41,685 -492	-1%	-$52.6K	0.52%	52
2017 Q2	$4.36M	Sell	42,177 -273	-0.6%	-$26.9K	0.58%	50
2017 Q1	$4.15M	Buy	42,450 +6,753	+19%	+$647K	0.56%	51
2016 Q4	$3.16M	Sell	35,697 -8,619	-19%	-$784K	0.44%	62
2016 Q3	$4.28M	Buy	+44,316	New	+$4.22M	0.61%	50
2014 Q3	–	Sell	-6,750	Closed	-$578K	–	290
2014 Q2	$578K	Buy	+6,750	New	+$532K	0.08%	151
2014 Q1	–	Sell	-6,000	Closed	-$454K	–	226
2013 Q4	$454K	Sell	6,000 -1,500	-20%	-$106K	0.09%	131
2013 Q3	$524K	Sell	7,500 -22,500	-75%	-$1.47M	0.11%	124
2013 Q2	$1.74M	Buy	+30,000	New	+$1.73M	0.43%	75

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Baker Avenue Asset Management's IBB Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of iShares Biotechnology ETF (IBB) in Q4 2023, closing a stake of 264 shares — an estimated $32.3K sold.

Baker Avenue Asset Management first reported a position in IBB in Q2 2013 and held it in 33 quarters. The position peaked at $13.2M in Q4 2019. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2023.

Baker Avenue Asset Management reported no remaining iShares Biotechnology ETF position as of Q4 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 264 iShares Biotechnology ETF shares in Q4 2023, an estimated $32.3K.
Baker Avenue Asset Management first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 33 quarters.
Baker Avenue Asset Management's iShares Biotechnology ETF position peaked at $13.2M in Q4 2019.
874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.